Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduction of Remifentanil-related Complications
Sponsor: Seoul National University Hospital
Summary
This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.
Official title: Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-11-01
Completion Date
2026-12-01
Last Updated
2023-12-01
Healthy Volunteers
No
Conditions
Interventions
Remifentanil (Limited) - Target Controlled Infusion system
Limit max plasma concentration to 9.8 ng/ml
Remifentanil (Control) - Target Controlled Infusion system
Use 20 ng/ml as max plasma concentration
Locations (1)
Seoul National University Hospital
Seoul, South Korea